Durability and efficacy of solbinsiran, a GalNAc-conjugated siRNA targeting ANGPTL3, in adults with mixed dyslipidaemia (PROLONG-ANG3): a double-blind, randomised, placebo-controlled, phase 2 trial

Kausik K. Ray(Imperial College London), Ena Oru(Eli Lilly (United States)), Robert S. Rosenson(Mount Sinai Hospital), Jeremiah Jones(Eli Lilly (United States)), Xiaosu Ma(Eli Lilly (United States)), Jennie Walgren(Eli Lilly (United States)), Axel Haupt(Eli Lilly (United States)), Subodh Verma(St. Michael's Hospital), Daniel Gaudet(Université de Montréal), Stephen J. Nicholls(Monash University), Giacomo Ruotolo(Eli Lilly (United States))

The Lancet

April 2, 2025

10.1016/s0140-6736(25)00507-0

Cited by 60

Abstract

Related Papers

No related papers found

Powered by citation graph analysis